Pharmacokinetic Individualisation of Zidovudine Therapy. Current State of Pharmacokinetic-pharmacodynamic Relationships

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1996 Apr 1

PMID 8983861

Citations 11

Authors

R M Hoetelmans

D M Burger

P L Meenhorst

J H Beijnen

Affiliations

Soon will be listed here.

Abstract

Zidovudine is the cornerstone of current antiretroviral treatment of human immunodeficiency virus (HIV) infection. Its use, however, frequently leads to adverse reactions, including myelosuppression. Zidovudine pharmacokinetics show large interindividual variation with indications of pharmacokinetic-pharmacodynamic relationships, but a clear therapeutic window has not yet been defined. Individualisation of zidovudine therapy with monitoring of drug concentrations might be desirable. This review considers (intracellular) monitoring of zidovudine and anabolites for individualisation of zidovudine therapy and the achievements in describing pharmacokinetic-pharmacodynamic relationships so far.

Citing Articles

Molecular properties prediction, anticancer and anti-inflammatory activities of some pyrimido[1,2-b]pyridazin-2-one derivatives.

Zeiz A, Kawtharani R, Elmasri M, Khawaja G, Hamade E, Habib A Bioimpacts. 2024; 14(2):27688.

PMID: 38505674 PMC: 10945296. DOI: 10.34172/bi.2023.27688.

Efficacy of Zidovudine-Amikacin Combination Therapy and in a Rat Tissue Cage Infection Model against Amikacin-Resistant, Multidrug-Resistant .

Gong W, Zhao X, Wang G, Ma X, Huang J Microbiol Spectr. 2023; :e0484322.

PMID: 36946744 PMC: 10101109. DOI: 10.1128/spectrum.04843-22.

Combination of Colistin and Azidothymidine Demonstrates Synergistic Activity against Colistin-Resistant, Carbapenem-Resistant .

Chang Y, Yang T, Lu P, Lin S, Wang L, Wang S Microorganisms. 2020; 8(12).

PMID: 33322306 PMC: 7764370. DOI: 10.3390/microorganisms8121964.

Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants.

Asconape J Curr Neurol Neurosci Rep. 2018; 18(12):89.

PMID: 30302572 DOI: 10.1007/s11910-018-0897-4.

Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.

Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P Antimicrob Agents Chemother. 2009; 53(10):4086-95.

PMID: 19667288 PMC: 2764156. DOI: 10.1128/AAC.00419-09.

References

Ruhnke M, Bauer F, Seifert M, Trautmann M, Hille H, Koeppe P . Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1993; 37(10):2153-8. PMC: 192243. DOI: 10.1128/AAC.37.10.2153. View

Taburet A, Naveau S, Zorza G, Colin J, Delfraissy J, Chaput J . Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther. 1990; 47(6):731-9. DOI: 10.1038/clpt.1990.101. View

Blum M, Liao S, Good S, de Miranda P . Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988; 85(2A):189-94. View

Drusano G, Balis F, Gitterman S, Pizzo P . Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother. 1994; 38(8):1726-31. PMC: 284629. DOI: 10.1128/AAC.38.8.1726. View

Balzarini J, Pauwels R, Baba M, Herdewijn P, De Clercq E, Broder S . The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 1988; 37(5):897-903. DOI: 10.1016/0006-2952(88)90178-5. View

Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer F . Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol. 1991; 40(3):305-8. DOI: 10.1007/BF00315215. View

Shelton M, Portmore A, Blum M, Sadler B, Reichman R, Morse G . Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy. 1994; 14(6):671-7. View

Tosi P, Calabresi P, Goulette F, Renaud C, Darnowski J . Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res. 1992; 52(15):4069-73. View

Stretcher B, Pesce A, Hurtubise P, Frame P . Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monit. 1992; 14(4):281-5. DOI: 10.1097/00007691-199208000-00004. View

10.

Meng T, Fischl M, Boota A, Spector S, Bennett D, Bassiakos Y . Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med. 1992; 116(1):13-20. DOI: 10.7326/0003-4819-116-1-13. View

11.

Drew R, Weller S, Gallis H, Walmer K, Bartlett J, Blum M . Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1989; 33(10):1801-3. PMC: 172758. DOI: 10.1128/AAC.33.10.1801. View

12.

Volberding P, Lagakos S, Koch M, Pettinelli C, Myers M, Booth D . Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990; 322(14):941-9. DOI: 10.1056/NEJM199004053221401. View

13.

Sette P, Narciso P, Tozzi V, Camporiondo M, Galgani S, LEONI G . Low-dose zidovudine for AIDS. Lancet. 1989; 1(8647):1136-7. DOI: 10.1016/s0140-6736(89)92410-0. View

14.

Gitterman S, Drusano G, Egorin M, Standiford H . Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther. 1990; 48(2):161-7. DOI: 10.1038/clpt.1990.131. View

15.

St Clair M, Richards C, Spector T, Weinhold K, Miller W, Langlois A . 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987; 31(12):1972-7. PMC: 175837. DOI: 10.1128/AAC.31.12.1972. View

16.

Gelmon K, Montaner J, Fanning M, Smith J, Falutz J, Tsoukas C . Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS. 1989; 3(9):555-61. DOI: 10.1097/00002030-198909000-00001. View

17.

Kong X, Zhu Q, Vidal P, WATANABE K, Polsky B, Armstrong D . Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother. 1992; 36(4):808-18. PMC: 189428. DOI: 10.1128/AAC.36.4.808. View

18.

Collins J, Unadkat J . Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989; 17(1):1-9. DOI: 10.2165/00003088-198917010-00001. View

19.

Langtry H . Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989; 37(4):408-50. DOI: 10.2165/00003495-198937040-00003. View

20.

Toyoshima T, Kimura S, Muramatsu S, TAKAHAGI H, Shimada K . A sensitive nonisotopic method for the determination of intracellular azidothymidine 5'-mono-, 5'-di-, and 5'-triphosphate. Anal Biochem. 1991; 196(2):302-7. DOI: 10.1016/0003-2697(91)90470-e. View